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Abstract
Background: The capacity of multiple comparisons to produce false positive findings in genetic association studies is 
abundantly clear. To address this issue, the concept of false positive report probability (FPRP) measures "the probability 
of no true association between a genetic variant and disease given a statistically significant finding". This concept 
involves the notion of prior probability of an association between a genetic variant and a disease, making it difficult to 
achieve acceptable levels for the FPRP when the prior probability is low. Increasing the sample size is of limited 
efficiency to improve the situation.
Methods: To further clarify this problem, the concept of true report probability (TRP) is introduced by analogy to the 
positive predictive value (PPV) of diagnostic testing. The approach is extended to consider the effects of replication 
studies. The formula for the TRP after k replication studies is mathematically derived and shown to be only dependent 
on prior probability, alpha, power, and number of replication studies.
Results: Case-control association studies are used to illustrate the TRP concept for replication strategies. Based on 
power considerations, a relationship is derived between TRP after k replication studies and sample size of each 
individual study. That relationship enables study designers optimization of study plans. Further, it is demonstrated that 
replication is efficient in increasing the TRP even in the case of low prior probability of an association and without 
requiring very large sample sizes for each individual study.
Conclusions: True report probability is a comprehensive and straightforward concept for assessing the validity of 
positive statistical testing results in association studies. By its extension to replication strategies it can be demonstrated 
in a transparent manner that replication is highly effective in distinguishing spurious from true associations. Based on 
the generalized TRP method for replication designs, optimal research strategy and sample size planning become 
possible.
Background
The advent of the "omics" revolution caused molecular
epidemiologists to attempt to rapidly identify as many
associations between genetic variants (most often single
nucleotide polymorphisms [SNPs]) and diseases as possi-
ble. In fact, discoveries were announced at impressive
rates with respect to various diseases, particularly with
the introduction of high-throughput genotyping technol-
ogies and genome-wide association studies. Hoover ([1],
p .  1 4 )  s p e a k s  o f  a  " b l i z z a r d  o f  p o s i t i v e  f i n d i n g s " .  T h i s
came as no surprise to statisticians, as it is not uncom-
mon in "omics" studies to set a particular α-level and call
any association with a p-value below α significant [2].
I t  s o o n  b e c a m e  i n c r e a s i n g l y  c l e a r ,  h o w e v e r ,  t h a t  t h e
vast majority of these "discoveries" could not be repli-
cated in subsequent studies. Ioannidis [3] pointed out
that the findings from single association studies (which
are usually adaptations of the case-control design) consti-
tute "tentative knowledge" and must be interpreted with
exceptional caution. Initial findings often overestimated
the true effect size [4,5], and reviews have shown that "an
alarming proportion" ([6], p. 421) of initial findings of
associations between genetic variants and diseases were
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irreproducible [7,8]. As Pharoah et al. [9] noted, the most
likely explanation for this phenomenon was "that most
initial reports are false positive, and the most common
reason for this is simply chance/type I error, exacerbated
by publication bias" (p. 852).
In the context of identifying associations between
genetic variants and diseases and to overcome the prob-
lem of having too many false positives, Wacholder et al.
[10] introduced the concept of false positive report prob-
ability (FPRP). The FPRP measures "the probability of no
true association between a genetic variant and disease
given a statistically significant finding" and can be used to
decide whether a finding is deserving attention or not.
The FPRP depends on the prior probability of an associa-
tion between the genetic variant and the disease, on the
α-level, and on the power of the statistical test. It is
important to mention that if the prior probability is low,
the FPRP cannot reach acceptable levels, even in the case
of very high power of the statistical test.
To further address this point, the concept of True
Report Probability (TRP) for statistical hypothesis tests is
introduced by analogy to the positive predictive value
(PPV) of a diagnostic test. The TRP concept is extended
to combine the results of several studies to provide a
method for maximizing the probability of "significant"
associations between a genetic variant and a disease
being true (even in the case of low prior probability of an
association, and without requiring extreme sample sizes).
The framework can be used by researchers to design
more conclusive research strategies.
Methods and Results
Analogy between Diagnostic and Statistical Testing
Diagnostic testing is used to separate cases from non-
cases in a given population. The set-up is usually summa-
rized by a four-fold table where each cell represents the
absolute number of individuals for the different combina-
tions of outcome (disease D+ vs. no disease D-) and test
result (positive T+ vs. negative T-) (see Additional file 1:
Appendix A, Table A1). Sensitivity (proportion of dis-
eased individuals who tested positive) and specificity
(proportion of healthy individuals who tested negative)
are the two key properties of a diagnostic test. Moreover,
the positive predictive value of a diagnostic test is defined
as the probability of the disease given a positive test
result.
The PPV is related to sensitivity and specificity through
Bayes' theorem:
where P(D+) is the prevalence of the disease (which
may be derived from cross-sectional studies), Sens the
sensitivity, and Spec the specificity.
If the disease prevalence is low (around 0.001), the PPV
obtained by applying one diagnostic test is low (<0.1),
even for high values of sensitivity and specificity. How-
ever, the PPV can be increased by using more than one
diagnostic test successively in individuals who tested pos-
itive in previous tests. This is illustrated by the HIV
example using the Elisa and Western blot tests succes-
sively (see Additional file 1: Appendix A, Tables A2 and
A3).
The sensitivity and specificity of the Elisa and Western
blot tests is in this example assumed to be 0.95 and 0.99,
respectively, and the prevalence of HIV in a given popula-
tion to be 0.001. If only the Elisa test is performed in the
initial population of 1'000'000 individuals, the PPV of this
test is as low as 0.087, whereas the number of individuals
who tested positive is 10'940. If subsequently the Western
blot test is applied in Elisa-positive individuals, the HIV
prevalence in this sub-population equals the positive pre-
dictive value of the Elisa test (0.087), and the PPV
increases to 0.9. The example illustrates the benefits of
"replication" and its impact on the confidence in a con-
firmed positive finding.
True Report Probability
The concepts of diagnostic testing can be adapted to
investigate associations between a genetic variant and a
disease. The null hypothesis (H0) of the statistical test is
that there is no association between a specific genetic
variant and a disease, while the alternative hypothesis
(H1) states an association (see Table 1, which gives a com-
plete overview of the correspondence between diagnostic
and statistical testing).
The PPV of diagnostic testing corresponds to the true
report probability in statistical testing, i.e. the probability
of a true association, given a statistically significant
result:
where π is the prior probability of an association. Esti-
mation of π is context-dependent and can be based on
previous studies (Dubé et al., [11]) or on subject-matter
considerations (Ziegler et al., [12]; Stephens & Balding,
[13]). Also, sensitivity analysis can be undertaken to
assess the effect of a range of prior probabilities on the
TRP.
An interesting property of the TRP (which is related to
the false positive report probability introduced by
Wacholder  et al. [10] through TRP = 1 - FPRP) is its
direct analogy with the PPV. The TRP can be viewed as
the posterior probability of an association which reflects
the update of the prior probability through the results of a
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replication study. In contrast, it is not possible to directly
relate the FPRP with a prior probability.
Figure 1 shows the TRP as a function of the prior prob-
ability of an association π and for several combinations of
power and α-level. As can be seen, even in the event of
very high power (≈0.95), the TRP remains low when the
prior probability of an association is low. For instance, the
TRP is below 0.5 when the prior probability is less than
0.01, meaning that less than 50 percent of associations
declared as being statistically significant are indeed true
associations. A TRP of 0.5 is neither encouraging nor
reassuring, as the level of certainty with a significant
result corresponds to the outcome probability of tossing a
coin.
Effect of Replication on TRP
In analogy to repeated diagnostic testing, the TRP as
defined in (2) can be extended to the case of replication
studies, with α and 1 - β having the same values in each
study. The TRP obtained after k-1 replication studies is
then used as the prior probability for the kth replication
study, i.e. the (k + 1)th study.
This formula can be replaced by a simpler formula (see
additional file 1: Appendix B for the proof):
It can be seen that in (4) TRP(k+1) only depends on the
prior probability π, on α, and on 1-β, but not on the TRP
of the previous step, which avoids the need for iterative
calculations.
Figure 2 represents, for different power levels (identical
across all studies of a replication design; α = 0.05 in all
studies) the TRP after 1, 2, 3, and 4 studies as a function
of the prior probability π of an association. It becomes
evident that the TRP cannot exceed 0.5 in the case of only
one replication study when the prior probability is below
0.001, even when the power is optimal (i.e. close to unity).
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Figure 1 TRP as a function of the prior probability. TRP as a func-
tion of prior probability (abscissa), α-level (1% and 5%, corresponding 
to the purple and blue curves, respectively), and power.
Figure 2 TRP as a function of the prior probability and number of 
studies. TRP as a function of prior probability (abscissa), power, and 
number of studies (α = 5% in all studies). The three blue, green, red, and 
black curves represent the case of one, two, three, and four studies, re-
spectively.
Table 1: Correspondence of characteristics of diagnostic 
and statistical testing.
Diagnostic test Statistical test
Presence of disease (D+) Association (H1 true)
Absence of disease (D-) No association (H0 true)
Positive result (T+) Rejecting H0
Negative result (T-) Retaining H0
Sensitivity = P(T+ | D+) Power = P(H0 rejected | H1 true) = 
1 - β
1 - Specificity = 1 - P(T- | D-) = 
P(T+ | D-)
Significance level = P(H0 rejected 
| H0 true) = α
Prevalence of disease = P(D+) Prior probability of association = 
P(H1 true) = π
Positive predictive value = PPV
= P(D+ | T+)
True report probability = TRP
= P(H1 true | H0 rejected)
= 1 - P(H0 true | H0 rejected)Weitkunat et al. BMC Medical Research Methodology 2010, 10:47
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In addition, increasing the power exerts only a small
effect on the TRP, compared to conducting a replication
study, which is reflected in the small elevation of the TRP
curve upon increasing the power, as compared to much
larger shift in the event of conducting replications. In
fact, replication studies are mandatory in order to sub-
stantially increase the confidence in the findings, espe-
cially when the prior probability is very small. This is of
particular relevance in multi-variable genome-wide asso-
ciation research, where often little to no prior knowledge
of genetic disease mechanisms is available.
Formula (4) can be used to determine the appropriate
research strategy. Given α and π of the initial study, the
power and number of replication studies can be deter-
mined in order to achieve a desired TRP.
Finding the Appropriate Research Strategy
The problem is illustrated in Figure 2. When, for exam-
ple, the prior probability is 0.01 and a TRP of 0.8 is
desired, the researcher has two choices: either to conduct
three studies with a power of 0.60 each, or two studies
with a power of 0.99 each. In both cases, in order to
increase the power from 0.60 to 0.99, an increase in the
overall (i.e. across studies) sample size is required.
To understand which of the two strategies (i.e. two or
three studies) is more efficient, formula (4) can be rear-
ranged:
In (5), the power of each study is interpreted as a func-
tion of the TRP for various values of the prior probability
π and number of replications k (note that α is assumed to
be constant across the studies). Figure 3 (left panel) illus-
trates the situation for π = 0.015 and 2, 3, and 4 studies.
Both Figure 3 (left panel) and formula (5) can be used to
determine the power of each study when the prior proba-
bility of an association π and the number of studies are
given. Assuming that the TRP should be 0.8, the α-level
0.05 and the prior probability 0.015, it follows that the
r e q u i r e d  p o w e r  o f  o n e  i n d i v i d u a l  s t u d y  m u s t  b e  0 . 8 1 ,
0.32, or 0.20 if two, three, or four successive studies are
performed, respectively.
Since the power largely depends on the sample size and
the α-level, it is possible to determine the minimum sam-
ple size required to achieve a desired power at a given α-
level. To illustrate this relationship, the power curves
contained in Figure 3 (right panel) are shown for the
study design suggested by Wacholder et al. [10] (see
Additional file 1: Appendix C for details). The plots illus-
trate how sample size and the proportion of individuals
with both the disease and the genetic variant under inves-
tigation (q) are related to power.
The graph can also be used in the reverse manner:
given q, it is possible to estimate the required sample size
in order to achieve a desired power. For instance, if q
equals 0.2 and a power 0.8 is required, the sample size
should be at least 820 (corresponding to a power of pre-
cisely 0.798). Based on the fact that power is a function of
TRP (Figure 3, left panel) and of sample size (Figure 3,
right panel), it is possible to establish a link between the
final TRP and the required sample size by plotting the
two panels of Figure 3 back to back, with power being the
common ordinate.
Figure 3 can therefore be used for parsing from the
desired TRP (left X-axis) to the required sample size
(right X-axis) by following the vertical and horizontal
lines through the power axis (and vice versa). By fixing
the desired TRP and the number of studies, for instance
to TRP = 0.8 and k = 2, it is possible to determine the
required power (0.81 in the example) on the power axis
and the corresponding sample size for a specific value of
q; e.g. for q = 0.2 the sample size would be n = 860.
Similarly, by initially fixing the power to 0.5, the sample
size (per study) must be n = 420 and the corresponding
TRP will be 0.60 after two studies (0.95 after three stud-
ies). By considering different scenarios of power, number
of replication studies, and TRP, the replication strategies
contained in Table 2 can be compared.
To assess the influence of the prior probability, a similar
graph can be plotted with the prior probability on the left
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Figure 3 Relationship between TRP and sample size via power. 
Relationships among TRP, power, and sample size for two, three, and 
four studies (green, red, and black curves, respectively). The prior prob-
ability is assumed to be 0.015 (α = 5% in all studies).Weitkunat et al. BMC Medical Research Methodology 2010, 10:47
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X-axis and various curves representing TRP levels. Figure
4 displays some combinations of TRP levels and numbers
of studies. It is used analogically to Figure 3. The sample
size is estimated given a desired TRP and an assumed
prior probability of an association.
Discussion
The concept of TRP was introduced by analogy to the
PPV of diagnostic testing and extended to consider the
effects of replication studies. The PPV and TRP are about
assessing the validity of positive findings and are poste-
rior probabilities. As with the positive predictive value,
which can be calculated for a battery of sequentially
administered diagnostic tests, calculation of the true
report probability can be extended in a straightforward
way to research designs involving replication studies.
Through this property, the TRP supports the selection of
efficient research strategies.
As often when concepts are translated from one
domain to another, the analogy between statistical testing
as conducted in replicated association studies and diag-
nostic testing conducted in clinical settings does not hold
completely: in sequential diagnostic testing, different
testing procedures are applied to the same individuals,
while the same (statistical) testing procedures are con-
ducted in different individuals in replication studies.
While this difference is a logical consequence of the dif-
ferent domains of diagnostic testing on one hand and sta-
tistical testing of associations on the other, the
correspondence of the concepts of PPV and TRP is com-
prehensive, in particular regarding the key aspect of
updating available a priori knowledge: as with the PPV,
the TRP depends heavily on the prior probability of an
association and cannot reach convincing values in one
single pass when the prior probability is low, even if the
power of the underlying statistical test is high. By extend-
ing the TRP concept to replication studies it becomes evi-
dent that replication is more efficient than increasing the
sample size with regard to raising the validity of positive
findings. As joint analysis is more powerful than separate
analyses of replication studies (Skol et al., [14]), it is a rea-
sonable approach if the main research objective is to dis-
cover unknown associations. Likewise, joint analysis may
be advantageous for obtaining more precise effect esti-
mates than a smaller replication sample can provide. If,
however, avoiding false discoveries is of prime impor-
tance, it is necessary to conceive research strategies
which plan for replications.
The replication strategy has also been advanced by
Zehetmayer et al. [15] who "propose multi-stage proce-
dures controlling either the family-wise error rate
(FWER) or the false discovery rate (FDR) and derive
asymptotically optimal stopping boundaries and sample
size allocations (across stages) to maximize the power of
the procedure". To avoid further confusion from invalid,
especially false-positive reports, it is important that ratio-
nal research strategies are implemented in association
studies (cf. [16]).
Based on the proposed methods, it is possible to esti-
mate the required power/sample size required to achieve
a desired TRP, given a prior probability of the association
and a certain α-level. The described methodology allows
for assessing whether it would be more favourable to per-
form two, three or more replication studies rather than
fewer but larger (and more powerful) studies.
Conclusions
This paper introduces the concept of true report proba-
bility (TRP) by analogy to diagnostic testing. As the con-
cept extends to conducting replication studies, it
supports designing effective research strategies. It is
shown that replication is more effective in distinguishing
s p u r i o u s  f r o m  t r u e  a s s o c i a t i o n s  t h a n  i s  i n c r e a s i n g  t h e
power of individual studies. A framework is provided to
Figure 4 Relationship between prior probability and sample size 
via power. Relationships among prior probability, power, and sample 
size for combinations of TRPs and numbers of studies (α = 5% in all 
studies).
Table 2: Replication strategies to achieve a desired TRP (α = 
0.05, π = 0.015, q = 0.20).
Number of
studies
Sample size
per study/Total
Power per
study
Final TRP
after k studies
2 860/1720 0.81 0.80
420/840 0.50 0.60
3 260/780 0.32 0.80
420/1260 0.50 0.95
4 140/560 0.20 0.80Weitkunat et al. BMC Medical Research Methodology 2010, 10:47
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support designing the most appropriate research strategy
in order to maximise the confidence in "significant" sta-
tistical association test results.
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